Merck, Inc.
🇵🇭Philippines
ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)
Phase 2
Completed
- Conditions
- Herpes Zoster
- Interventions
- Biological: Zoster Vaccine, Live
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 309
- Registration Number
- NCT00546819
GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)
Phase 2
Completed
- Conditions
- Anxiety Disorder
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 38
- Registration Number
- NCT00546624
A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)
Phase 3
Completed
- Conditions
- Ocular HypertensionGlaucoma
- Interventions
- First Posted Date
- 2007-10-18
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 170
- Registration Number
- NCT00546286
Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1512
- Registration Number
- NCT00545584
Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)
Phase 4
Completed
- Conditions
- Ocular HypertensionOpen Angle Glaucoma
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 176
- Registration Number
- NCT00545064
Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)
Phase 2
Terminated
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: MK0533
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 346
- Registration Number
- NCT00543959
MK0767 and Metformin Combination Study (0767-028)
Phase 3
Terminated
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 114
- Registration Number
- NCT00543738
MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)
Phase 3
Terminated
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00543816
A Study to Determine the Effectiveness and Tolerability of MK8141 in Patients With High Blood Pressure (MK-8141-006)
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT00543413
Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)
Phase 3
Terminated
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 610
- Registration Number
- NCT00543751
© Copyright 2025. All Rights Reserved by MedPath